CoChat

The AT(N) framework for Alzheimer's disease in adults with Down syndrome

Open access
Rafii, Michael S., Ances, Beau M., Schupf, Nicole, Krinsky‐McHale, Sharon J., Mapstone, Mark, Silverman, Wayne, Lott, Ira, Klunk, William, Head, Elizabeth, Christian, Brad, Lai, Florence, Rosas, H. Diana, Zaman, Shahid, Petersen, Melissa E., Strydom, Andre, Fortea, Juan, Handen, Benjamin, O'Bryant, Sid · 2020 · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Cited by 33

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

The National Institute on Aging in conjunction with the Alzheimer's Association (NIA-AA) recently proposed a biological framework for defining the Alzheimer's disease (AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms. By using these same biomarkers, individuals with Down syndrome (DS), who are genetically predisposed to developing AD, can also be placed more precisely along the AD continuum. The A/T(N) framework is therefore thought to provide an objective manner by which to select and enrich samples for clinical trials. This new framework is highly flexible and allows the addition of newly confirmed AD biomarkers into the existing AT(N) groups. As biomarkers for other pathological processes are validated, they can also be added to the AT(N) classification scheme, which will allow for better characterization and staging of AD in DS. These biological classifications can then be merged with clinical staging for an examination of factors that impact the biological and clinical progression of the disease. Here, we leverage previously published guidelines for the AT(N) framework to generate such a plan for AD among adults with DS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dad2.12062

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 33

Metadata

Authors
Rafii, M. S., Ances, B. M., Schupf, N., Krinsky‐McHale, S. J., Mapstone, M., Silverman, W., Lott, I., Klunk, W., Head, E., Christian, B., Lai, F., Rosas, H. D., Zaman, S., Petersen, M. E., Strydom, A., Fortea, J., Handen, B., & O'Bryant, S.
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2020-01
Volume
12
Issue
1
Pages
e12062-e12062
ISSN
2352-8729 (ISSN-L)
OpenAlex
W3096362384
Cited by
33
References
17
FWCI
2.39
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The AT(N) framework for Alzheimer's disease in adults with Down syndrome. https://app.cochat.ai/papers/10.1002/dad2.12062
The paper
Rafii, M. S., Ances, B. M., Schupf, N., Krinsky‐McHale, S. J., Mapstone, M., Silverman, W., Lott, I., Klunk, W., Head, E., Christian, B., Lai, F., Rosas, H. D., Zaman, S., Petersen, M. E., Strydom, A., Fortea, J., Handen, B., & O'Bryant, S. (2020). The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. https://doi.org/10.1002/dad2.12062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.